Guillaume Becker

Dr. Guillaume Becker


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2020 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
DLDominique Levêque
Dominique Levêque
GBGuillaume Becker
Guillaume Becker
KBKarin Bilger
Karin Bilger
SNShanti Natarajan-Amé
Shanti Natarajan-Amé

6 September 2019 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
DLDominique Levêque
Dominique Levêque
GBGuillaume Becker
Guillaume Becker
Introduction: Therapeutic drug monitoring in oncology is used to prevent major toxicities of selected anticancer agents due to overexposure by individualizing the dose based on a pharmacokinetic target. Areas covered: Numerous studies relating a relation between pharmacokinetic variability and toxicity have been reported since the eighties but very few have been implemented in clinical practice due to a lack of validation and harmonization, logistical constraints and reluctance from oncologists. Following recent recommendations, this paper highlights the current validated applications of pharmacokinetic monitoring in oncology focusing on the safety of anticancer therapies. Expert opinion: Paradoxically given the oldness of the agents, guidelines of dose adjustment have been recently available for intravenous busulfan, 5-fluorouracil and high dose methotrexate. Interestingly, besides the enhancement of tolerability, it applies to potential curative clinical situations. In an era of personalized oncology that integrates complex molecular factors in the treatment of cancer, education is needed for oncologists to show the benefits of this valuable (even old) resource for the safety of patients. Therapeutic drug monitoring for busulfan, 5-fluorouracil and methotrexate will still hold in the future unless more active agents are available in the concerned indications.

15 May 2017 in International Journal of Pharmacokinetics
Verified
Journal Article
Closed access
DLDominique Levêque
Dominique Levêque
GBGuillaume Becker
Guillaume Becker
ETElise Toussaint
Elise Toussaint
LFLuc-Matthieu Fornecker
Luc-Matthieu Fornecker
CPCatherine Paillard
Catherine Paillard
Methotrexate is an antifolate agent used in the treatment of autoimmune diseases and various types of cancers. It is a unique antiproliferative agent because it can be administered by multiple routes with a wide variation of dosing. Methotrexate pharmacokinetics have generated numerous papers focusing on descriptive data and pharmacodynamics. Methotrexate is one of the rare anticancer agents which pharmacokinetics are routinely monitoring to control excessive toxicity when administrated at high dose (>1 g/m2). The identification of transporters involved in its disposition has permitted the understanding and the prevention of most drug interactions. Pharmacogenetic factors affecting the expression of MRP2 and OATP1B1 partly explain the interindividual variability of methotrexate clearance. The remaining challenge in methotrexate pharmacokinetics is to further understand unexplained delayed renal elimination despite the implementation of preventive measures.

1 February 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
FNFlore Nardella
Flore Nardella
MBMorgane Beck
Morgane Beck
PCPierre Collart-Dutilleul
Pierre Collart-Dutilleul
GBGuillaume Becker
Guillaume Becker
CBCoralie Boulanger
Coralie Boulanger
GUGenevieve Ubeaud-sequier
Genevieve Ubeaud-sequier

29 April 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HJHervé Javelot
Hervé Javelot
WISSAM EL-HAGEWISSAM EL-HAGE
WISSAM EL-HAGE
GMGuillaume Meyer
Guillaume Meyer
GBGuillaume Becker
Guillaume Becker
BMBruno Michel
Bruno Michel
CHCoraline Hingray
Coraline Hingray
Click on the article title to read more.

30 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ASAmelia-Naomi SABO
Amelia-Naomi SABO
SJSarah JANNIER
Sarah JANNIER
GBGuillaume Becker
Guillaume Becker
JLJean-Marc Lessinger
Jean-Marc Lessinger
Natacha Entz-WerleNatacha Entz-Werle
Natacha Entz-Werle
VKVéronique Kemmel
Véronique Kemmel
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with other antineoplastic agents. However, in cancer, there is no consensus on sirolimus TDM. In the RAPIRI phase I trial, the combination sirolimus + irinotecan was evaluated as a new treatment for refractory pediatric cancers. Blood sampling at first sirolimus intake (D1) and at steady state (D8), followed by LC/MS2 analysis, was used to develop a population pharmacokinetic model (Monolix® software). A mono-compartmental model with first-order absorption and elimination best fit the data. The only covariate retained for the final model was “body surface area” (D1 and D8). The model also demonstrated that 1.5 mg/m2 would be the recommended sirolimus dose for further studies and that steady-state TDM is necessary to adjust the dosing regimen in atypical profiles (36.4% of the population). No correlation was found between sirolimus trough concentrations and efficacy and/or observed toxicities. The study reveals the relevance of sirolimus TDM in pediatric oncology as it is needed in organ transplantation.